German biotechnology company
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa). 
TME Pharma develops drugs using technology yielding -RNA molecules, which are of mirror-image configuration compared to naturally occurring -RNA molecules. The company calls these agents Spiegelmers, from "Spiegel", the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes.
Products.
Some Spiegelmer candidates were in clinical trials. 
A Spiegelmer (NOX-A12, olaptesed pegol) was under development as a combination therapy for a number of cancer indications. NOX-A12 targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA.
A different Spiegelmer (NOX-E36, emapticap pegol) was tested for the treatment of progressive diabetic nephropathy. Favorable results were reported in June 2014 in a company press release. NOX-E36 targets MCP-1, also called CCL2. 
A third Spiegelmer (NOX-H94, lexaptepid pegol) was in a clinical trial for the treatment of anemia of chronic disease.